Literature DB >> 7730335

A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells.

K A Marquette1, D D Pittman, R J Kaufman.   

Abstract

Factor VIII is the coagulation factor deficient in the X-chromosome-linked bleeding disorder hemophilia A. Factor VIII is homologous to blood coagulation factor V, both having a domain structure of A1-A2-B-A3-C1-C2. Previous transfection studies demonstrated that factor VIII is 10-fold less efficiently expressed than the homologous coagulation factor, factor V. The inefficient expression correlated with interaction of the factor VIII primary translation product with the protein chaperonin BiP in the lumen of the endoplasmic reticulum. In contrast, factor V was not detected in association with BiP and was secreted efficiently. To determine whether specific amino acid sequences within factor VIII inhibit secretion, we have studied the secretion of factor VIII deletion and factor VIII/factor V chimeric proteins upon transient transfection of COS-1 monkey cells. A chimeric factor VIII protein that contained the A1- and A2-domains of factor V was secreted with a similar efficiency as wild-type factor V, whereas the complementary chimera having the A1- and A2-domains of factor VIII was secreted with low efficiency, similar to wild-type factor VIII. These results suggested that sequences within the A1- and A2-domains were responsible for the low secretion efficiency of factor VIII. Secretion of A1-domain-deleted factor VIII was increased approximately 10-fold compared to wild-type factor VIII or A2-domain-deleted factor VIII. Expression of the factor VIII A1-domain alone did not yield secreted protein, whereas expression of the factor VIII A2-domain alone or the factor V A1-domain or A2-domain alone directed synthesis of secreted protein. Secretion of a hybrid in which the carboxyl-terminal 110 amino acids of the A1-domain were replaced by homologous sequences from the factor V A1-domain was also increased 10-fold compared to wild-type factor VIII, however, the secreted protein was not functional and the heavy and light chains were not associated. These results localize a 110-amino acid region within the A1-domain that inhibits factor VIII secretion. This region is clustered with multiple short peptide sequences that have potential to bind BiP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730335     DOI: 10.1074/jbc.270.17.10297

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Expression of human coagulation factor VIII in a human hybrid cell line, HKB11.

Authors:  Baisong Mei; Yaoqi Chen; Jianmin Chen; Clark Q Pan; John E Murphy
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

2.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

3.  Molecular mechanisms of missense mutations that generate ectopic N-glycosylation sites in coagulation factor VIII.

Authors:  Wei Wei; Saurav Misra; Matthew V Cannon; Renchi Yang; Xiaofan Zhu; Reid Gilmore; Min Zhu; Bin Zhang
Journal:  Biochem J       Date:  2018-03-06       Impact factor: 3.857

4.  Removal of single-site N-linked glycans on factor VIII alters binding of domain-specific monoclonal antibodies.

Authors:  Jasmine Ito; Wallace Hunter Baldwin; Courtney Cox; John F Healey; Ernest T Parker; Emily R Legan; Renhao Li; Surinder Gill; Glaivy Batsuli
Journal:  J Thromb Haemost       Date:  2021-12-17       Impact factor: 5.824

Review 5.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

6.  Intracellular retention of a factor VIII protein with an Arg2307-->Gln mutation as a cause of haemophilia A.

Authors:  J Voorberg; R T de Laaf; P M Koster; J A van Mourik
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

7.  Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.

Authors:  Kerry L Dooriss; Gabriela Denning; Bagirath Gangadharan; Elisabeth H Javazon; David A McCarty; H Trent Spencer; Christopher B Doering
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

8.  Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector.

Authors:  Ali Ramezani; Robert G Hawley
Journal:  Blood       Date:  2009-05-21       Impact factor: 22.113

9.  Defects in Protein Folding and/or Quality Control Cause Protein Aggregation in the Endoplasmic Reticulum.

Authors:  Juthakorn Poothong; Insook Jang; Randal J Kaufman
Journal:  Prog Mol Subcell Biol       Date:  2021

10.  Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum.

Authors:  Juthakorn Poothong; Anita Pottekat; Marina Siirin; Alexandre Rosa Campos; Adrienne W Paton; James C Paton; Jacqueline Lagunas-Acosta; Zhouji Chen; Mark Swift; Niels Volkmann; Dorit Hanein; Jing Yong; Randal J Kaufman
Journal:  Blood       Date:  2020-05-21       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.